In virologically suppressed patients with chronic hepatitis B virus (HBV) infection, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not affect their rates of viral suppression, according to the final 96-week analysis of a phase III study.
Online messaging apps may be helpful in spreading trustworthy information regarding the coronavirus disease 2019 (COVID-19) pandemic, allaying the public’s distress and promoting well-being, according to a recent Singapore study.
There appears to be a higher thrombus burden and poorer outcomes in patients with the novel coronavirus disease (COVID-19) with ST-segment elevation myocardial infarction (STEMI), according to a recent study.
Eight months into the pandemic, the world is still in the heat of fighting a contagion that we’ve no treatment for and no protection from. So far, what we’re able to achieve is a stalemate against COVID-19. Science remains our best hope – a vaccine against SARS-COV-2 with long-lasting protection.
Laboratory and radiological features are insufficient to distinguish the coronavirus disease 2019 (COVID-19) from other non-SARS-CoV-2 respiratory viral infections, according to a new Singapore study. On the other hand, anosmia and dysgeusia are reliable indicators of COVID-19.
A sex- and age-matched case-control study of 140 adults withattention-deficit/hyperactivity disorder (ADHD) finds that Toxoplasma gondii seropositivity is associated with a 2.8-fold increase in the odds of ADHD and reveals its significant association with ADHD symptom severity.
The combination therapy sofosbuvir-seraprevir appears to be effective and well tolerated in patients with chronic hepatitis C virus (HCV) genotype 1 infection without cirrhosis, results of a phase III trial have shown.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Percutaneous coronary intervention (PCI), compared with coronary artery bypass grafting (CABG), in the revascularization of left main coronary artery (LMCA) disease may lead to death, myocardial infarction (MI), or stroke in patients with moderate or severe left ventricular (LV) dysfunction, reveals a study.